Recent successes of tissue bioengineering in ophthalmology highlighted

Article

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Dr. Ellis-Behnke and his team at MIT conducted in vivo experiments in young and adult hamsters. After making a deep cut in the superior colliculus, the researchers injected a clear substance containing a self-assembling material made of peptides. This serves as a matrix for new cell growth. The researchers observed new axon growth first in young animals, then carried out a similar experiment in adults in a way that removed all visually-guided orienting behavior, Dr. Ellis-Behnke said.

Six weeks after the cut was made, the researchers began testing the animals and found complete regeneration and functional vision in all but two of the treated animals. In those two, the lack of improvement apparently was due to surgical error, Dr. Ellis-Behnke said. While the animals displayed some signs of healing, it was insufficient to drive their behavior.

In separate experiments, Dr. Ellis-Behnke and colleagues showed that axon growth could be seen in live animals.

Ultimately, they hope to apply these findings on self-assembling peptides and axon growth to humans, Dr. Ellis-Behnke concluded.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.